As a global healthcare company, BioTherapeutics is aimed on saving and sustaining the lives of people with rare conditions. Over the last two decades, we've committed ourselves to providing therapies for patients across a broad range of treatment needs, such as:
Primary immunodeficiency (PI), including Common Variable Immune Deficiency (CVID) and X-Linked Agammaglobulinemia (XLA)Please see Important Risk Information |
Alpha-1 antitrypsin deficiency (AATD)Please see Important Risk Information |
Severe congenital Protein C deficiency (SCPCD)Please see Important Risk Information |
Treatment of hypovolemiaPlease see Important Risk Information |
We share the understanding of healthcare professionals, patients and caregivers that the challenges of rare conditions do not end with therapy. That's why BioTherapeutics also offers insurance assistance, patient assistance programs that provide continued access to therapy such as the GARDian program, and partnerships with advocacy organizations like the Immune Deficiency Foundation (IDF), Jeffrey Modell Foundation (JMF) and Alpha-1 Foundation. We're committed to building a network of programs and support for people challenged by rare conditions.
BioTherapeutics believes in giving people with rare conditions more ordinary days, so they can spend time on the things that make life extraordinary.
A sterile, nonpyrogenic preparation of albumin in a single-dosage
Sterile, stable, lyophilized preparation of purified alpha 1-proteinase inhibitor
